Strategic Partnerships Leverage Bay Area Lyme Ventures investment to pursue co development and funded pilots with Lyme and tick borne disease clinics and academic centers.

Academic Licensing Virginia Tech licensing of Borrelia peptidoglycan antigen detection signals a path for sponsored research and enterprise licensing with hospitals and research institutions seeking advanced Borrelia diagnostics.

Lyme Portfolio Growth Nanotrap Urine Test enables more sensitive direct Lyme detection, complemented by the Bartonella IFA Serology Panel, creating upsell opportunities for specialty and reference labs needing high sensitivity vector borne testing.

Mid Market Focus With a small to mid sized team and revenues targeting a niche lab segment, prioritize regional hospitals, independent reference labs, and specialized diagnostics networks with flexible pricing and scalable deployment.

Pipeline Commercialization The combination of ongoing product development and recent partnerships supports multi site adoption; coordinate regulatory readiness and field support to accelerate go to market for new tests.